The Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial development. The approved project is scheduled to be ...
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer ...
After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...
Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a ...
Can WuXi AppTec’s Integrated Discovery Platform Power Oncology? WuXi AppTec’s integrated platform combines high-authority screening, pharmacology, and early assessment in a single end-to-end system.
OK! Magazine on MSN
Sam Neill gives miraculous cancer update after failed chemo treatments fueled death fears: 'It looked like I was on the way out'
Sam Neill said he is feeling well after learning he is cancer-free in an interview with Australia’s 7News published Sunday, ...
There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...
4don MSN
Key molecular dynamic could boost cancer treatments while limiting stem cell transplant rejection
A key molecular dynamic could be the key to fighting tumors while allowing patients to still receive life-saving cell ...
PD-1 and LAG-3 are both inhibitory immune checkpoints known for limiting T cell activity in cancer. Blocking PD-1 and LAG-3 ...
The FDA granted regenerative medicine advanced therapy (RMAT) designation to Orca-Q, a second-generation investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results